Johnson and Johnson to Quicken Development of Ebola Virus Vaccine
The Wall Street Journal
By Erin McCarthy
Johnson & Johnson said Thursday it is accelerating the development of a vaccine regimen against Ebola, in an effort to help curb the virus that has overwhelmed West Africa.
The regimen consists of two vaccine components from Johnson & Johnson's Crucell NV and Denmark-based biotech company Bavarian Nordic, BAVA.KO +3.23% both of which are developing vaccines against filoviruses, including Ebola. The combination vaccine from the two companies aims to protect against the Zaire strain, which is responsible for the current outbreak across West Africa.
Johnson & Johnson said the vaccine program is being accelerated to allow for clinical trials in humans in early 2015, after promising results in preclinical studies.
Click here to read the full story.